

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During consultation, a consultee highlighted an urgent need for access to novel treatments for younger, fitter patients with chronic lymphocytic leukaemia as currently only fludarabine, cyclophosphamide and rituximab (FCR) or venetoclax plus obinutuzumab via the Cancer Drugs Fund is available to them.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will appraise ibrutinib with venetoclax within its marketing authorisation for all people with untreated chronic lymphocytic leukaemia.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes were made to the draft scope to highlight any potential equality issues.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to potential equality issues were identified during the scoping process.

Approved by Associate Director (name): Ross Dent

Date: 04/04/2022